Bladder-sparing treatment for muscle-invasive bladder carcinoma using immune checkpoint inhibitors
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bladder-sparing treatment for muscle-invasive bladder carcinoma using immune checkpoint inhibitors
Authors
Keywords
-
Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 191, Issue -, Pages 104137
Publisher
Elsevier BV
Online
2023-09-15
DOI
10.1016/j.critrevonc.2023.104137
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-world study of chemotherapy plus immunotherapy versus chemotherapy alone as neoadjuvant treatment guided bladder-sparing therapy for localized muscle-invasive bladder cancer.
- (2022) Yali Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial
- (2022) Emma Hall et al. EUROPEAN UROLOGY
- Survival after Neoadjuvant/Induction Combination Immunotherapy versus Combination Platinum‐based Chemotherapy for Locally Advanced (Stage III ) Urothelial Cancer
- (2022) Sarah MH Einerhand et al. INTERNATIONAL JOURNAL OF CANCER
- Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer
- (2022) Ben-Max de Ruiter et al. EUROPEAN UROLOGY
- Phase II clinical study of tislelizumab combined with nab-paclitaxel (TRUCE-01) for muscle-invasive urothelial bladder carcinoma: Bladder preservation subgroup analysis.
- (2022) Yuanjie Niu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Atezolizumab plus Trimodal Therapy in Patients with localized Muscle-Invasive Bladder Cancer
- (2021) Gautier Marcq et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- EA8185: Phase II study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), ECOG-ACRIN/nrg collaboration.
- (2021) Monika Joshi et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study.
- (2021) Andrew James Weickhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II clinical study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results for primary analyses and survival. BTCRC-GU15-023.
- (2021) Monika Joshi et al. JOURNAL OF CLINICAL ONCOLOGY
- INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients.
- (2021) Parminder Singh et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303
- (2021) Matthew D Galsky et al. Future Oncology
- Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients with Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC)
- (2021) Mark A. Socinski et al. Clinical Lung Cancer
- Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.
- (2021) Arjun Vasant Balar et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.
- (2021) Matt D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report
- (2021) Chuanzhen Cao et al. Frontiers in Immunology
- Organ-Sparing Strategies in Muscle-Invasive Bladder Cancer
- (2021) J Alfred Witjes et al. Cancer Management and Research
- Combination therapies involving checkpoint-inhibitors for treatment of urothelial carcinoma: a narrative review
- (2021) Gerald B. Schulz et al. Translational Andrology and Urology
- Bladder-sparing treatment options in localized muscle-invasive bladder cancer
- (2020) Gregory J Nason et al. Expert Review of Anticancer Therapy
- Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502).
- (2020) Andrew James Weickhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Secondary analysis of PURE-01: Role of FDG-PET/CT in evaluating lymph node involvement of patients with muscle invasive bladder cancer (MIBC) receiving neoadjuvant pembrolizumab and radical cystectomy (RC).
- (2020) Laura Marandino et al. JOURNAL OF CLINICAL ONCOLOGY
- Bladder preservation in muscle-invasive bladder cancer: a comprehensive review
- (2020) Judy Hamad et al. International Braz J Urol
- Double immune checkpoint blockade in advanced NSCLC
- (2020) Annapaola Mariniello et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
- (2020) J. Alfred Witjes et al. EUROPEAN UROLOGY
- The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
- (2020) Florent Petitprez et al. Frontiers in Immunology
- 776P Phase II trial of concurrent nivolumab in urothelial bladder cancer with radiation therapy in localized/locally advanced disease for chemotherapy ineligible patients [NUTRA trial]
- (2020) U.N. Vaishampayan et al. ANNALS OF ONCOLOGY
- Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆
- (2020) M. Bandini et al. ANNALS OF ONCOLOGY
- Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
- (2020) Nick van Dijk et al. NATURE MEDICINE
- Bladder Cancer
- (2020) Andrew T. Lenis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Systematic review of neoadjuvant therapy by immune checkpoint inhibitors before radical cystectomy: where do we stand?
- (2020) Simone Albisinni et al. Minerva Urologica E Nefrologica
- Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer
- (2020) Côme Tholomier et al. Translational Andrology and Urology
- Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer
- (2019) David J. Einstein et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- A Nationwide Population Based Analysis of Organ-Confined Muscle-Invasive Bladder Cancer Patients Not Receiving Curative Intent Therapy in Sweden from 1997 to 2014.
- (2019) Dan-Olle Westergren et al. JOURNAL OF UROLOGY
- Organ preservation in bladder cancer: an opportunity for truly personalized treatment
- (2019) Yee Pei Song et al. Nature Reviews Urology
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- (2019) Thomas Powles et al. NATURE MEDICINE
- Clinical Complete Response after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Call for Standardized Assessments and Definitions
- (2019) Jared S. Winoker et al. European Urology Focus
- A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer
- (2018) Omar Fahmy et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy
- (2018) Dennis Robins et al. UROLOGY
- Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis
- (2018) Herney Andrés García-Perdomo et al. WORLD JOURNAL OF UROLOGY
- The Reciprocity between Radiotherapy and Cancer Immunotherapy
- (2018) Yifan Wang et al. CLINICAL CANCER RESEARCH
- Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial
- (2018) Jürgen E. Gschwend et al. EUROPEAN UROLOGY
- Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study
- (2018) Andrea Necchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer
- (2018) Di (Maria) Jiang et al. Clinical Genitourinary Cancer
- Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience
- (2017) Nicholas J. Giacalone et al. EUROPEAN UROLOGY
- Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic
- (2017) Girish S. Kulkarni et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Landmarks in the treatment of muscle-invasive bladder cancer
- (2017) Niyati Lobo et al. Nature Reviews Urology
- Evolving Treatment of Advanced Urothelial Cancer
- (2017) Srikala S. Sridhar Journal of Oncology Practice
- Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
- (2016) J. M. Pitt et al. ANNALS OF ONCOLOGY
- Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer
- (2016) Kimberley S. Mak et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Immune modulation in advanced radiotherapies: Targeting out-of-field effects
- (2015) Gerard G. Hanna et al. CANCER LETTERS
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- (2015) Leisha A. Emens et al. Cancer Immunology Research
- The Natural History of Clinically Complete Responders to Neoadjuvant Chemotherapy for Urothelial Carcinoma of the Bladder
- (2014) Alexa Meyer et al. JOURNAL OF UROLOGY
- Correlation of Pathologic Complete Response with Survival After Neoadjuvant Chemotherapy in Bladder Cancer Treated with Cystectomy: A Meta-analysis
- (2013) Fausto Petrelli et al. EUROPEAN UROLOGY
- Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
- (2012) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience
- (2011) Jason A. Efstathiou et al. EUROPEAN UROLOGY
- The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy
- (2009) Nicholas J. Hellenthal et al. BJU INTERNATIONAL
- Bladder Preservation in Selected Patients with Muscle-Invasive Bladder Cancer by Complete Transurethral Resection of the Bladder Plus Systemic Chemotherapy: Long-Term Follow-up of a Phase 2 Nonrandomized Comparative Trial with Radical Cystectomy
- (2008) Eduardo Solsona et al. EUROPEAN UROLOGY
- Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology
- (2008) Ahmad Shabsigh et al. EUROPEAN UROLOGY
- Outcome of Patients Who Refuse Cystectomy after Receiving Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
- (2007) Harry W. Herr EUROPEAN UROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started